February 5, 2018 / 12:21 PM / 5 months ago

BRIEF-Bristol-Myers Squibb Says Key Lung Cancer Trial Meets Main Goal

Feb 5 (Reuters) - Bristol-Myers Squibb Co:

* PIVOTAL PHASE 3 CHECKMATE -227 STUDY DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL (PFS) WITH THE OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH HIGH TUMOR MUTATION BURDEN (TMB)

* BRISTOL-MYERS - PHASE 3 CHECKMATE -227 STUDY MET CO-PRIMARY ENDPOINT OF PFS WITH OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY

* BRISTOL-MYERS - TRIAL WILL CONTINUE AS PLANNED TO ASSESS OPDIVO-YERVOY COMBO FOR OTHER CO-PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH PD-L1 TUMORS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below